Category REGENERATIVE MEDICINE

PIER MARIA FORNASARI
2021-03-08

The challenges of CAR T-cell therapy for pediatric B-ALL. RESTORE launched Fragments of Life: A success in the frontier of medicine becomes a video game.

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the challenges associated with CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (ALL). Discovering the best treatment phasing with other immunotherapies, such as blinatumomab and inotuzumab, improving the toxicity profile, and CAR T-cell persistence are some of the remaining

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-02-24

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Despite dramatic improvements in survival, multiple myeloma (MM) remains largely incurable, and most patients develop disease that is refractory to available treatment options. A paper just published on Blood Advances by researchers of Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Westwood, Division of Gastroenterology, University of Toledo, Division of Hematology and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-02-24

European Society Blood and Marrow Transplantation Annual Report shows the rise of CAR-T Cells in Europe during year 2019 and changes in medical practices in the field of hematopoietic cell transplantation over 30 years.

Hematopoietic cell transplantation (HCT) is an established procedure for many acquired or inherited disorders of the hematopoietic system, benign or neoplastic, including those of the immune system, and as enzyme replacement in metabolic disorders. The activity survey of the EBMT, describing the status of HCT, has become an instrument with which to observe trends and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-02-08

Diffuse large B-cell lymphoma (DLBCL): FDA Grants Approval of 4th CAR-T Cell Therapy for Adults with Relapsed or Refractory DLBCL.

Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial Breyanzi demonstrated sustained responses in patients who achieved a CR with median duration of response not reached Grade ≥3 cytokine release syndrome and Grade ≥3 neurologic toxicities following Breyanzi treatment occurred in 4% and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-02-07

CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will perform an accelerated assessment of the Marketing Authorisation Application (MAA) for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel). Accelerated assessment is

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-01-23

Creating a Safe CAR T-Cell Therapy to Fight Solid Tumors in Children

Scientists at Children’s Hospital Los Angeles develop newer CAR T therapy that promises to be more effective and less toxic for children with neuroblastoma. Chimeric Antigen Receptor T-cell therapy—CAR T—has revolutionized leukemia treatment. Unfortunately, the therapy has not been effective for treating solid tumors including childhood cancers such as neuroblastoma. Preclinical studies using certain CAR

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-01-18

Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise Hopes

A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both therapies work by switching on a gene that promotes production of fetal hemoglobin, said Dr. Lewis Hsu, chief medical officer of the Sickle Cell Disease Association

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2021-01-15

The Future of CAR T cells in multiple myeloma

Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the past decade, it remains an incurable disease. Patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen has transformed the treatment armamentarium of relapsed/refractory MM (RRMM), with unprecedented overall

Read More

No Comments InCAR-T